Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...
Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.
In type 1 diabetes, the immune system starts to destroy insulin-producing beta cells in the pancreas. Progressive loss of these cells destabilizes the body's glucose levels and drives the course of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results